» Articles » PMID: 32172441

Healthcare Utilization and Productivity Loss in Glioma Patients and Family Caregivers: the Impact of Treatable Psychological Symptoms

Overview
Journal J Neurooncol
Publisher Springer
Date 2020 Mar 16
PMID 32172441
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Gliomas are associated with significant healthcare burden, yet reports of costs are scarce. While many costs are unavoidable there may be treatable symptoms contributing to higher costs. We describe healthcare and societal costs in glioma patients at high risk for depression and their family caregivers, and explore relationships between costs and treatable symptoms.

Methods: Data from a multicenter randomized trial on effects of internet-based therapy for depressive symptoms were used (NTR3223). Costs of self-reported healthcare utilization, medication use, and productivity loss were calculated for patients and caregivers separately. We used generalized linear regression models to predict costs with depressive symptoms, fatigue, cognitive complaints, tumor grade (low-/high-grade), disease status (stable or active/progression), and intervention (use/non-use) as predictors.

Results: Multiple assessments from baseline through 12 months from 91 glioma patients and 46 caregivers were used. Mean overall costs per year were M = €20,587.53 (sd = €30,910.53) for patients and M = €5,581.49 (sd = €13,102.82) for caregivers. In patients, higher healthcare utilization costs were associated with more depressive symptoms; higher medication costs were associated with active/progressive disease. In caregivers, higher overall costs were linked with increased caregiver fatigue, cognitive complaints, and lower patient tumor grade. Higher healthcare utilization costs were related to more cognitive complaints and lower tumor grade. More productivity loss costs were associated with increased fatigue (all P < 0.05).

Conclusions: There are substantial healthcare and societal costs for glioma patients and caregivers. Associations between costs and treatable psychological symptoms indicate that possibly, adequate support could decrease costs.

Trial Registration: Netherlands Trial Register NTR3223.

Citing Articles

APPROACH: Analysis of Proton versus Photon Radiotherapy in Oligodendroglioma and Assessment of Cognitive Health - study protocol paper for a phase III multicentre, open-label randomised controlled trial.

Slevin F, Hudson E, Boele F, Powell J, Noutch S, Borland M BMJ Open. 2025; 15(2):e097810.

PMID: 40010843 PMC: 11865786. DOI: 10.1136/bmjopen-2024-097810.


Reporting standards in randomized controlled trials involving neuro-oncology caregivers: A systematic review report from the RANO-Cares working group.

Boele F, Hertler C, Sherwood P, Cachia D, Dirven L, Young J Neurooncol Pract. 2025; 12(1):19-33.

PMID: 39917763 PMC: 11798602. DOI: 10.1093/nop/npae086.


But at What Cost? Healthcare Utilization of Canadian Carer-Employees.

Ding R, Duxbury L Int J Environ Res Public Health. 2025; 21(12.

PMID: 39767525 PMC: 11675624. DOI: 10.3390/ijerph21121686.


Telehealth Utilization in Neuro-Oncology: Commentary on a Single Institution Experience After the COVID-19 Pandemic.

Sener U, Uhm J, Haddad T, Pritchett J Curr Oncol Rep. 2024; 26(11):1271-1276.

PMID: 39083169 DOI: 10.1007/s11912-024-01588-5.


High costs, low quality of life, reduced survival, and room for improving treatment: an analysis of burden and unmet needs in glioma.

Pohlmann J, Weller M, Marcellusi A, Grabe-Heyne K, Krott-Coi L, Rabar S Front Oncol. 2024; 14:1368606.

PMID: 38571509 PMC: 10987841. DOI: 10.3389/fonc.2024.1368606.


References
1.
Day J, Yust-Katz S, Cachia D, Wefel J, Katz L, Tremont I . Interventions for the management of fatigue in adults with a primary brain tumour. Cochrane Database Syst Rev. 2016; 4:CD011376. PMC: 8719625. DOI: 10.1002/14651858.CD011376.pub2. View

2.
Sherwood P, Price T, Weimer J, Ren D, Donovan H, Given C . Neuro-oncology family caregivers are at risk for systemic inflammation. J Neurooncol. 2016; 128(1):109-118. PMC: 4865431. DOI: 10.1007/s11060-016-2083-3. View